Beam Therapeutics develops gene editing medicines that change single DNA bases to treat serious diseases. BEAM reports earnings on Tue, Nov 3, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 29 | Canaccord Genuity | Maintained | Buy | |
| Oct 28 | Wedbush | Target lowered | Buy | |
| Sep 9 | Wedbush | Reiterated | Buy | |
| Aug 25 | HC Wainwright & Co. | Reiterated | Buy | |
| Jul 8 | B of A Securities | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in BEAM in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BEAM is in one of them and how their past BEAM trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BEAM in an article yet. Here's the latest on the wider market.
About Beam Therapeutics
Beam Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that develops gene editing medicines for patients with serious diseases. Its main approach is base editing, which changes a single DNA letter without cutting both strands of the DNA. Its lead programs target sickle cell disease and certain inherited liver and metabolic disorders. The company also has its own manufacturing capabilities for these therapies.
- Headquarters
- Cambridge, MA